Phillip Doyle from Doyle GxP discusses GxP principles for small biotechs. Covering areas such as when in the drug development journey quality and compliance principles should apply, how to apply them, and why GxP guidelines are important for creating an early culture of quality, you won't want to miss this session.

Join Egnyte's Product Experts for a series of live demonstrations of Egnyte's Life Sciences Solutions. Demos include functional tours of: GxP, Quality Document Management, and eTMF.

The estimated value of blockchain technology to the life sciences sector is predicted to be somewhere between $3B and $5.6B by 2025, primarily due to the imperative for secure communication between stakeholders organizing clinical trials. Join the discussion to learn how life science companies are starting to leverage blockchain technology to improve data integrity, security, and accessibility in modern clinical trials.

Decentralized Clinical Trials (DCTs) have increased in popularity during the pandemic. DCTs tout better patient participation, lower dropout rates, and more diverse patient pools. But as the world opens up and traditional clinical trial capacity returns to pre-pandemic levels, will DCTs maintain their popularity? Join industry experts from Bristol Myers Squibb (BMS) and Thread(R) as they discuss the merits and future of DCTs.

Developing new medicines is risky and costly. Recent public market volatility has led the $XBI (ETF that tracks the performance of the S&P® Biotechnology Index) to fall 60% from its 2021 high to the 2022 trough. In this light, biotech companies need to be creative in obtaining financing to support the development of needed medicines. In this session, Alok Tayi, founder of VIBE Bio DAO, will discuss innovative ways of capitalizing on programs & companies such that the organization has the resources required to help patients with novel medicines.